Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company’s late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcoming data in geographic atrophy and regulatory filings for Guillain-Barré syndrome.
Love described Annexon as a neuroimmunology company focused on the classical complement pathway, specifically C1q, which he said is the initiator of that pathway. He said the company’s approach is differentiated from other complement-targeting strategies because C1q “localizes and binds to disease tissue” across neuroinflammatory diseases affecting the body, brain and eye.
